In the treatment of highly aggressive neuroblastoma (NB), the upregulation of HO-1 limits the efficacy of bortezomib (11, 12) suggesting HO-1 inhibition may represent a molecular target in the clinical strategies against NB (13, 14). This evidence concerns the gene HMOX1 and neuroblastoma.